Phase 1b trial of enfortumab vedotin in combination with checkpoint inhibitors in patients with metastatic urothelial cancer.

Trial Profile

Phase 1b trial of enfortumab vedotin in combination with checkpoint inhibitors in patients with metastatic urothelial cancer.

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2017 Status changed from not stated to planning.
    • 01 Aug 2017 New trial record
    • 27 Jul 2017 According to a Seattle Genetics media release, this trial expected to start late in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top